This section provides information about bone health and bone-targeted therapies in metastatic prostate cancer. The most common site of metastasis for prostate cancer is the bone. Treatments used in cancer management can also have adverse effects on bones. Bone-related conditions in metastatic prostate cancer are one of the most important causes of morbidity and mortality. In bone-targeting treatments, resorption modulators and radiotherapy are the main components. Radionuclide agents are innovative treatments for targeting bones.